Valuation: Lexington Biosciences, Inc.

Market Cap 3.94K 2.81K 2.45K 2.32K 2.1K 270K 3.96K 27.74K 10.71K 137K 10.57K 10.33K 442K P/E 2022
-
P/E 2023 -
Enterprise Value 3.94K 2.81K 2.45K 2.32K 2.1K 270K 3.96K 27.74K 10.71K 137K 10.57K 10.33K 442K EV / Sales 2022
-
EV / Sales 2023 -
Free-Float
13.79%
Yield 2022 *
-
Yield 2023 -
28/11/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
23/08/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
24/05/24 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
01/05/24 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
29/04/24 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
28/11/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
04/09/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
30/05/23 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
03/05/23 Registered Plan Private Investments Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
01/05/23 Registered Plan Private Investments Inc. Auditor Raises 'Going Concern' Doubt CI
29/11/22 Registered Plan Private Investments Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
30/08/22 Registered Plan Private Investments Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
29/05/22 Registered Plan Private Investments Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Manager TitleAgeSince
Chief Executive Officer 62 15/04/2020
Director of Finance/CFO 68 -
Director TitleAgeSince
Director/Board Member 68 20/12/2016
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+87.32%+90.04% - - 2.74K
+0.37%+0.65%-24.57%+1.93% 178B
-0.69%+1.29%-3.10%+11.50% 118B
-0.20%-3.98%+6.47%+71.79% 58.92B
-0.24%+1.74%-3.26%-31.97% 49.29B
-0.22%-0.37%+10.27%+40.45% 48.17B
+1.61%+7.61%+32.47%-5.11% 33.72B
-1.49%-2.74% - - 27.76B
-1.17%+4.64%+42.17%-7.72% 25.5B
+1.02%+5.99%+6.51%-15.81% 22.1B
Average +8.63%+1.85%+8.37%+8.13% 62.32B
Weighted average by Cap. -0.08%+1.03%-3.19%+10.47%

Financials

2022 2023
Net sales - -
Net income -176K -126K -110K -103K -93.92K -12.05M -177K -1.24M -478K -6.13M -472K -461K -19.72M -177K -127K -110K -104K -94.67K -12.15M -178K -1.25M -482K -6.18M -476K -465K -19.88M
Net Debt - -
Logo Lexington Biosciences, Inc.
Lexington Biosciences Holdings Corp., formerly Lexington Biosciences Inc., is a Canada-based medical device company, which core business is to develop and commercialize non-invasive diagnostic product HeartSentry to monitor cardiovascular health by assessing the function of a person’s vascular endothelium - the vital innermost lining of a person’s cardiovascular system. The device measures the function of the endothelium, the cells that line all arteries and are critical to the prevention of atherosclerosis, heart attacks and stroke. The company is in the final stages of releasing the developed product for clinical studies. The Company's goal is to make HeartSentry accurate, quick, and cost effective so it can become the standard of care for cardiologists, general practitioners, and ultimately patients for first line evaluation of a person’s cardiovascular health.
Employees
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!